UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053124
Receipt number R000060624
Scientific Title The study on predicting recurrence of first-onset major depressive disorder using resting-state functional MRI
Date of disclosure of the study information 2023/12/18
Last modified on 2023/12/15 23:46:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study on predicting recurrence of first-onset major depressive disorder using resting-state functional MRI

Acronym

The study on Predicting REcurrence of first-onset major DEpressive disorder using Resting-state functional MRI (PREDERM study)

Scientific Title

The study on predicting recurrence of first-onset major depressive disorder using resting-state functional MRI

Scientific Title:Acronym

The study on Predicting REcurrence of first-onset major DEpressive disorder using Resting-state functional MRI (PREDERM study)

Region

Japan


Condition

Condition

Major depressive disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Major depression disorder (MDD) is known as a mental illness with frequent recurrence. The lifetime recurrence rate after symptom remission is approximately 60% in newly diagnosed MDD, and the recurrence rate increases with repeated depressive episodes. Multiple episodes and psychotic features have been reported as risk factors for recurrence, but it has been pointed out that these reports lack consistency.
The purpose of this study is to examine whether functional connectivity obtained by resting state functional MRI after antidepressant discontinuation predicts recurrence in newly diagnosed MDD in remission.

Basic objectives2

Others

Basic objectives -Others

Evaluation of differences in brain networks using rsfMRI in depression remission maintenance group and depression relapse group

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

recurrence of MDD

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

69 years-old >=

Gender

Male and Female

Key inclusion criteria

(Whole)
1. Each participant must have a level of understanding sufficient to agree to all tests including functional MRI and examinations required by the protocol and must sign an informed consent document.
2. right handed.

(Patients with MDD)
1. Participants must fulfill ICD-10 criteria for F32.
2. Currently in remission, defined as a HAM-D 17 score < 7 in 8 weeks or more.
(Healthy control)
1. No current or past psychiatric disorders.
2. HAM-D 17 score < 7.

Key exclusion criteria

(Patients with major depression)
1. Patients with any clinically significant psychiatric disorder other than ICD-10 criteria for F32.
2. Patients with any organic brain disease.
3. Patients with unstable medical illness.
(Healthy control)
Those who have a history of treatment for mood disorder or psychotic disorder in the third degree relative.

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Tomoyuki
Middle name
Last name Nakamura

Organization

Kurume university school of medicine

Division name

Neuropsychiatry

Zip code

8300011

Address

67 Asahimachi, Kurume city, Fukuoka, Japan.

TEL

+81-942-31-7613

Email

nakamura_tomoyuki@med.kurume-u.ac.jp


Public contact

Name of contact person

1st name Tomoyuki
Middle name
Last name Nakamura

Organization

Kurume university school of medicine

Division name

Neuropsychiatry

Zip code

8300011

Address

67 Asahimachi, Kurume city, Fukuoka, Japan

TEL

+81-942-31-7613

Homepage URL


Email

nakamura_tomoyuki@med.kurume-u.ac.jp


Sponsor or person

Institute

Kurume university school of medicine

Institute

Department

Personal name



Funding Source

Organization

Kurume university school of medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kurume University Medical Ethics Committee

Address

67 Asahimachi, Kurume city, Fukuoka, Japan.

Tel

0942-31-7200

Email

kcrc_jimu@kurume-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 12 Month 01 Day

Date of IRB

2023 Year 06 Month 19 Day

Anticipated trial start date

2023 Year 12 Month 15 Day

Last follow-up date

2027 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The purpose of this study is to examine whether functional connectivity obtained by resting state functional MRI after antidepressant discontinuation predicts recurrence in newly diagnosed MDD in remission.


Management information

Registered date

2023 Year 12 Month 15 Day

Last modified on

2023 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060624


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name